Updates

Ref: ADL/SE/2026-27/62 November 6, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We wish to inform you that the United States Food and Drug Administration (“US FDA”) has inspected the Formulations manufacturing facility of our Subsidiary, Pinnacle Life Science Private Limited at Baddi, Himachal Pradesh from 2nd to 6th of November 2026. On conclusion of the inspection, the company has received 3 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. There is no impact on financial, operation or other activities of the Company pursuant the observations received. The additional information pursuant to Industry Standards Note on Regulation 30 of the Listing Regulations is provided under Annexure A. This is for your information and records. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Annexure A November 6, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, In respect of the captioned matter, I, the undersigned, state and declare that the information and details provided in Form A, in compliance with Regulation 30(13) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is true, correct and complete to the best of my knowledge and belief. This is for your information and records. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Form A Disclosure by Aarti Drugs Limited regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [Regulation 30(13) – Disclosure of communication from regulatory, statutory, enforcement or judicial authority] Sr. Particulars Details 1. Name of the listed company The Communication is received by Wholly owned Subsidiary, Pinnacle Life Science Private Limited (Pinnacle) 2. Type of communication received Form 483 3. Date of receipt of communication November 6, 2026 4. Authority from whom communication United States Food and Drug Administration received (“US FDA”) 5. Brief summary of the material United States Food and Drug Administration contents of the communication (“US FDA”) has inspected the received, including reasons for Formulations manufacturing facility of our receipt of the communication Subsidiary, Pinnacle Life Science Private Limited at Baddi, Himachal Pradesh from 2nd to 6th of November 2026. On conclusion of the inspection, the company has received 3 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. 6. Period for which communication N.A would be applicable, if stated 7. Expected financial implications on There is no impact on financial, operation or the listed company, if any other activities of Pinnacle pursuant the above communication. 8. Details of any aberrations/non- On conclusion of the inspection, the company compliances identified by the has received 3 inspectional observations in authority in the communication Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. 9. Details of any penalty or restriction N.A or sanction imposed pursuant to the communication 10. Ac tion(s) taken by listed company The company will work closely with US FDA in with respect to the communication resolving all points. 11. An y other relevant information -